Evidence-based medical knowledge provider BMJ and the Lupus Foundation of America have announced a partnership to publish Lupus Science & Medicine, an open access journal dedicated to lupus. The journal will seek to provide an international focal point for clinicians and researchers across multiple disciplines
The Lupus Science & Medicine journal claims to be the first open access journal dedicated to the poorly understood and potentially life threatening disease, lupus. The journal will offer timely global access to the latest scientific advances in lupus. The title will officially launch early next year.
Lupus Science & Medicine will be edited by Jill P Buyon, Division Director of Rheumatology, Professor of Medicine at New York University School of Medicine, and Ronald F van Vollenhoven, Professor and Chief, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute, Stockholm, Sweden.
Lupus research is currently published in a wide array of journals, particularly those in the specialties of rheumatology, immunology, dermatology and nephrology. The new online title will offer scientists and clinicians a unique focal point for new developments in the understanding and treatment of this complex and unpredictable autoimmune disease, the causes of which are still not clear.
Lupus Science & Medicine is owned by the Lupus Foundation of America, and will be published by BMJ as a peer reviewed open access online title, with submissions on basic, clinical, translational, and epidemiological studies on all aspects of lupus and related diseases. In common with the other open access titles, published by BMJ, the journal will enjoy fast editorial decisions and short publication times, bringing the latest research on lupus to a global audience.
